News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
722,933 Results
Type
Article (42711)
Company Profile (295)
Press Release (679926)
Multimedia
Podcasts (84)
Webinars (13)
Section
Business (210535)
Career Advice (2094)
Deals (36654)
Drug Delivery (107)
Drug Development (83117)
Employer Resources (175)
FDA (16619)
Job Trends (15430)
News (356277)
Policy (33965)
Tag
Academia (2600)
Accelerated approval (5)
Adcomms (23)
Allergies (97)
Alliances (51535)
ALS (105)
Alzheimer's disease (1430)
Antibody-drug conjugate (ADC) (158)
Approvals (16613)
Artificial intelligence (303)
Autoimmune disease (27)
Automation (18)
Bankruptcy (372)
Best Places to Work (11771)
BIOSECURE Act (20)
Biosimilars (116)
Biotechnology (188)
Bladder cancer (88)
Brain cancer (34)
Breast cancer (352)
Cancer (2728)
Cardiovascular disease (209)
Career advice (1755)
Career pathing (31)
CAR-T (179)
CDC (27)
Cell therapy (485)
Cervical cancer (21)
Clinical research (68114)
Collaboration (972)
Company closure (3)
Compensation (634)
Complete response letters (25)
COVID-19 (2687)
CRISPR (59)
C-suite (296)
Cystic fibrosis (113)
Data (2797)
Decentralized trials (2)
Denatured (29)
Depression (54)
Diabetes (304)
Diagnostics (6490)
Digital health (21)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (134)
Drug pricing (130)
Drug shortages (30)
Duchenne muscular dystrophy (115)
Earnings (89065)
Editorial (42)
Employer branding (21)
Employer resources (150)
Events (116422)
Executive appointments (836)
FDA (18159)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (865)
Gene editing (130)
Generative AI (22)
Gene therapy (370)
GLP-1 (790)
Government (4594)
Grass and pollen (5)
Guidances (179)
Healthcare (19020)
Huntington's disease (29)
IgA nephropathy (36)
Immunology and inflammation (144)
Immuno-oncology (7)
Indications (36)
Infectious disease (2841)
Inflammatory bowel disease (150)
Inflation Reduction Act (9)
Influenza (56)
Intellectual property (111)
Interviews (323)
IPO (16847)
IRA (49)
Job creations (4061)
Job search strategy (1493)
Kidney cancer (13)
Labor market (49)
Layoffs (509)
Leadership (18)
Legal (8391)
Liver cancer (78)
Lung cancer (385)
Lymphoma (195)
Machine learning (9)
Management (59)
Manufacturing (371)
MASH (86)
Medical device (13508)
Medtech (13513)
Mergers & acquisitions (20464)
Metabolic disorders (792)
Multiple sclerosis (94)
NASH (17)
Neurodegenerative disease (112)
Neuropsychiatric disorders (32)
Neuroscience (2085)
NextGen: Class of 2025 (6642)
Non-profit (4534)
Now hiring (45)
Obesity (415)
Opinion (238)
Ovarian cancer (94)
Pain (113)
Pancreatic cancer (108)
Parkinson's disease (178)
Partnered (22)
Patents (281)
Patient recruitment (138)
Peanut (51)
People (59547)
Pharmaceutical (91)
Pharmacy benefit managers (22)
Phase I (21142)
Phase II (29975)
Phase III (22442)
Pipeline (1557)
Policy (190)
Postmarket research (2654)
Preclinical (9017)
Press Release (68)
Prostate cancer (131)
Psychedelics (32)
Radiopharmaceuticals (257)
Rare diseases (452)
Real estate (6263)
Recruiting (67)
Regulatory (23335)
Reports (50)
Research institute (2373)
Resumes & cover letters (359)
Rett syndrome (9)
RNA editing (9)
RSV (45)
Schizophrenia (87)
Series A (148)
Series B (98)
Service/supplier (12)
Sickle cell disease (60)
Special edition (19)
Spinal muscular atrophy (150)
Sponsored (32)
Startups (3733)
State (2)
Stomach cancer (14)
Supply chain (72)
Tariffs (61)
The Weekly (53)
Vaccines (763)
Venture capitalists (47)
Weight loss (264)
Women's health (41)
Worklife (16)
Date
Today (139)
Last 7 days (506)
Last 30 days (2445)
Last 365 days (32243)
2025 (15237)
2024 (35772)
2023 (40630)
2022 (51798)
2021 (56330)
2020 (54791)
2019 (47403)
2018 (35771)
2017 (33139)
2016 (32665)
2015 (38616)
2014 (32517)
2013 (27631)
2012 (29731)
2011 (30492)
2010 (28499)
Location
Africa (782)
Alabama (58)
Alaska (7)
Arizona (248)
Arkansas (14)
Asia (40991)
Australia (6555)
California (7136)
Canada (2261)
China (645)
Colorado (304)
Connecticut (308)
Delaware (183)
Europe (87591)
Florida (1071)
Georgia (237)
Idaho (58)
Illinois (622)
India (27)
Indiana (355)
Iowa (16)
Japan (215)
Kansas (108)
Kentucky (27)
Louisiana (13)
Maine (64)
Maryland (995)
Massachusetts (5338)
Michigan (240)
Minnesota (432)
Mississippi (3)
Missouri (85)
Montana (28)
Nebraska (25)
Nevada (77)
New Hampshire (65)
New Jersey (1988)
New Mexico (29)
New York (2005)
North Carolina (1065)
North Dakota (8)
Northern California (3143)
Ohio (227)
Oklahoma (15)
Oregon (39)
Pennsylvania (1552)
Puerto Rico (16)
Rhode Island (36)
South America (1163)
South Carolina (33)
South Dakota (1)
Southern California (2662)
Tennessee (118)
Texas (1060)
United States (26578)
Utah (212)
Virginia (182)
Washington D.C. (71)
Washington State (611)
West Virginia (4)
Wisconsin (66)
722,933 Results for "essa pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025
May 8, 2025
·
6 min read
Biotech Bay
ESSA Pharma to Present at the Jefferies Global Healthcare Conference
ESSA Pharma Inc. today announced that the Company will be presenting at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 p.m. ET in New York.
May 30, 2024
·
1 min read
Business
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2024.
May 14, 2024
·
10 min read
Press Releases
ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024
February 11, 2025
·
6 min read
Biotech Bay
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
ESSA Pharma Inc. today announced that the Company will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 2:30 p.m. ET in Toronto, Canada.
April 9, 2024
·
1 min read
Business
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023
ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2023.
February 13, 2024
·
11 min read
Biotech Bay
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
ESSA Pharma Inc. today announced that the Company will be participating in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET.
February 6, 2024
·
1 min read
Press Releases
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
December 17, 2024
·
8 min read
Business
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023
ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2023.
December 12, 2023
·
11 min read
Business
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
September 11, 2024
·
1 min read
1 of 72,294
Next
